OBJECTIVES: To estimate the economic consequences of replacing the normal tablets of quetiapine with Seroquel XR® in the treatment of schizophrenia in Poland. METHODS: Based on the established model of the economic consequences of schizophrenia treatment, we calculated the cost of treating schizophrenia with quetiapine in Poland. Expenditures for the purchase of medicines, hospital costs and the costs of lost productivity were highlighted. The analysis was performed from a societal perspective, taking into account the Payer’s perspective, in one‑year time horizon.  RESULTS: The use of Seroquel XR® will increase the population of patients who comply with the recommended treatment, which will reduce the likelihood of suicide, absenteeism, and the hospitalisation rate. The reimbursement of Seroquel XR® could generate annual budget savings of PLN 8.6 million ( 2150 thousands Euro), if Seroquel XR® were used in 31% of quetiapine‑treated patients with schizophrenia. The maximum savings resulting from the reimbursement of quetiapine prolonged release tablets (Seroquel XR®) could amount to PLN 27.6 million (6900 thousands Euro) per year. CONCLUSIONS: The reimbursement of Seroquel XR® with the reimbursement limit at the level of the reimbursement limit for normal tablets of quetiapine is profitable for the state budget – it will not only bring budgetary savings, but also allow patients to return to active life, which is crucial in the case of schizophrenia.